DHTL
SME CapDocmode Health Technologies Ltd.
Pharma
Docmode Health Technologies Ltd. operates in HealthTech, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust is a red flag, timing is unclear, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Technical trend unavailable.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Sept 2025
Bad · 0/100Rev -24% YoY · PAT -107% YoY · margin expansion
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹17.9 Cr | -24.4% | -16.4% |
| EBITDA | ₹0.8 Cr | NDF | +245.5% |
| Operating margin | 4.5% | NDF | +706 bps |
| PAT | ₹-0.1 Cr | -106.6% | NDF |
| PAT margin | -0.5% | NDF | +596 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Issuer presentation review pending
Docmode Health Technologies Ltd. operates in HealthTech, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Sept 2025. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trend score and candlestick chart
Trend score is pending. The candlestick chart remains available for manual review.
Technical chart
DHTLweekly · 1Y-60.2%Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
OVERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- FCF yield is supportive at 20.8%.
- Cash flow contributes 5/10 to the score.
- Growth contributes 9/25 to the score.
Main drags
- Altman Z is 1.6, in distress territory.
- Promoter pledge is 37.4%.
- Penalty bucket subtracts 7 points.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Low Trust: Claim history is still being built. It ranks around the 1st percentile of the scored universe and 1st percentile within Pharma. Main check: promoter alignment is weak at 17/100.
Low Trust Lite: FCF yield is 18.8%. Key concern: Promoters have pledged 37.4% of holding.
Avoid relying on management narrative unless turnaround evidence is hard and recent.
overall median 67 · Pharma: 1st pctile, median 70 · SME: 1st pctile, median 65
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Low Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸FCF yield is 18.8%.
Trust risks
- ▸Promoters have pledged 37.4% of holding.
- ▸Promoter holding fell 17.9%.
- ▸Altman Z is 1.64.
- ▸2 recent quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- —
- P/B
- 1.76
- EV/EBITDA
- 42.21
- Market Cap
- 14.50Cr
Profitability
- ROE
- -21.70%
- ROCE
- -0.29%
- ROA
- -3.87%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 43.00%
- EPS 5Y
- 8.00%
- Revenue 3Y
- 50.00%
- EPS 3Y
- 1.00%
Balance Sheet
- Debt/Equity
- 0.90
- Interest Coverage
- 0.15×
- Altman Z
- 1.61
- Book Value
- 26.20
Cash Flow
- FCF Yield
- 20.76%
- FCF Positive Y
- 1/5
- OCF
- 6.68 Cr
- EPS TTM
- -4.68
Shareholding
- Promoter Hold
- 29.50%
- Promoter Pledge
- 37.40%
- Momentum 52W
- 10%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.